ON AIR STAR
00:00:00 | 3:02:50

DONATE!

close

FROM THIS EPISODE

President Obama wants to reduce the threat of Iran building an atomic bomb. Iran’s President Rouhani wants to free his economy from economic sanctions. Is that enough for a permanent deal after a yearlong temporary agreement that ends next Monday? Negotiations are resuming tomorrow.

Also, a doctor treated for Ebola dies in Omaha, and a drug that’s been recognized by health agencies as greatly reducing the spread of AIDS. Is that counterproductive, by discouraging the use of condoms by gay and bisexual men?

Photo: Omani Foreign Minister Yusuf bin Alawai greets US Secretary of State John Kerry in Muscat, Oman, on November 9, 2014 before negotiations about the future of Iran's nuclear program. (State Department)

Producers:
Benjamin Gottlieb
Katie Cooper
Jenny Hamel

Doctor Treated for Ebola Dies in Omaha 6 MIN, 30 SEC

The tenth Ebola patient to be treated here in the US has died at the Nebraska Medical Center in Omaha. Dr. Martin Salia was flown there after a medical evacuation from Freetown Sierra Leone. Dr. Dan Johnson of the Nebraska Medical Center says that Salia was critically ill when he arrived, suffering from respiratory and kidney failure. Betsy McKay is Atlanta Bureau Chief for the Wall Street Journal. She covers public health and global health issues.

Guests:
Betsy McKay, Wall Street Journal (@betswrites)

Iran’s Nuclear Program: Once Again, It’s Down to the Wire 34 MIN, 7 SEC

A year ago, six nations forged a temporary agreement with Iran to limit its nuclear program in exchange for a partial lifting of economic sanctions. That led to ongoing negotiations, which are set to expire next Monday. Russia, Israel, Saudi Arabia and Western Europe all have major stakes in the outcome, which could re-shape the political contours of the Middle East. President Obama and Iran’s President Rouhani both want an agreement, but Republicans could pass new sanctions or the Supreme Leader could kill any deal. We hear about possible benefits, potential risks and political consequences. 

Guests:
Laura Rozen, Al-Monitor (@lrozen)
Thomas Erdbrink, New York Times (@ThomasErdbrink)
Emad Kiyaei, American Iranian Council (@ekiyaei)
Reuel Marc Gerecht, Foundation for Defense of Democracies (@followFDD)

More:
Rozen on continuing Iranian nuclear talks, likelihood of breakthrough
Erdbrink on Iranian economic pain and the nuclear negotiations
Kiyaei on Iran as America’s best hope in defeating the Islamic State
Gerecht on Iran's diplomatic path to the bomb

The Fight over the Pill to Prevent HIV 9 MIN, 14 SEC

Truvada is a daily medication recognized by the World Health Organization, the Centers for Disease Control and Prevention and other health agencies as greatly reducing the risk of contracting the HIV virus. But one AIDS organization warns of a “public health disaster in the making.” This week, the Los Angeles-based AIDS Healthcare Foundation will be taking out advertisements asking, “What if you’re wrong about PrEP?” That’s another name for a type of drug called Truvada.

Guests:
Josh Barro, Business Insider / KCRW's Left, Right & Center' (@jbarro)
Jeremiah Johnson, Treatment Action Group (@TAGTeam_Tweets)

More:
Barro on AIDS Healthcare Foundation's fight against Truvada
Treatment Action Group on Governor Cuomo's NY State plan to end AIDS

Events

View All Events

New Episodes

iTUNES SPOTIFY
AMAZON RDIO
FACEBOOK EMAIL
TWITTER COPY LINK
FACEBOOK TWITTER

Player Embed Code

COPY EMBED